Autres langues Vaxcyte, Inc.

Actions

PCVX

US92243G1085

Temps réel estimé Cboe BZX Autres places de cotation 16:04:08 30/04/2024			Varia. 5j.	Varia. 1 janv.
60,58 ^USD	-0,73%		-0,16%	-3,22%

25/04	Un initié de Vaxcyte a vendu des actions pour une valeur de 928 845 $, selon un récent dépôt auprès de la SEC	MT
22/04	Un initié de Vaxcyte a vendu des actions d'une valeur de 490 199 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	25/04
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	22/04
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03
Vaxcyte Q4 Loss Widens	27/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	15/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	02/02
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	01/02
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	31/01
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	31/01
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	31/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vaxcyte, Inc.

Actions

PCVX

US92243G1085

Autres langues

Filtres